Devin C Flaherty1, Simon Lavotshkin1, John R Jalas2, Hitoe Torisu-Itakura3, Daniel D Kirchoff1, Myung S Sim4, Delphine J Lee5, Anton J Bilchik6. 1. Department of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA. 2. Department of Pathology, Providence Saint John's Health Center, Santa Monica, CA. 3. Melanoma Research Program and Department of Immunology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA. 4. Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA. 5. Dirks/Dougherty Laboratory for Cancer Research and Department of Translational Immunology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA. 6. Department of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA; Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA; California Oncology Research Institute, Los Angeles, CA. Electronic address: bilchika@jwci.org.
Abstract
BACKGROUND: Retrospective data indicate that immunoprofiling of T cell markers can be prognostic in colon cancer. Prospective T cell immunoprofiling of colon cancer has not been well defined for patients whose lymph nodes are ultrastaged. STUDY DESIGN: A prospective cohort was selected from patients enrolled in an ongoing phase II multicenter trial of nodal ultrastaging for colon cancer. Primary tumor specimens from 89 patients were analyzed by immunohistochemistry for the T cells CD3(+), CD4(+), CD8(+), and FOXP3(+). Lymphocyte populations were quantified with digital image analysis. Results were examined for their association with 5-year disease-free survival along with TNM stage and clinicopathologic variables. RESULTS: Longer disease-free survival was associated with higher CD3(+) counts at the invasive margin (IM) (p = 0.005), higher CD8(+) counts at the tumor center (TC) and IM (p = 0.002), a lower CD4(+)/CD8(+) ratio at the TC+IM (p = 0.027), and a higher CD8(+)/FOXP3(+) ratio at the TC+IM (p = 0.020). After multivariable analysis, CD8(+) at the TC+IM (p = 0.002), the CD8(+)/FOXP3(+) ratio at the TC+IM (p = 0.004), and the number of tumor-positive lymph nodes (p = 0.003) remained significant. CONCLUSIONS: This is the first prospective demonstration of the prognostic utility of immunoprofiling in colon cancer after nodal ultrastaging. Staging based on tumor immunoprofile can augment TNM staging and provide targets for specific immunotherapies.
BACKGROUND: Retrospective data indicate that immunoprofiling of T cell markers can be prognostic in colon cancer. Prospective T cell immunoprofiling of colon cancer has not been well defined for patients whose lymph nodes are ultrastaged. STUDY DESIGN: A prospective cohort was selected from patients enrolled in an ongoing phase II multicenter trial of nodal ultrastaging for colon cancer. Primary tumor specimens from 89 patients were analyzed by immunohistochemistry for the T cells CD3(+), CD4(+), CD8(+), and FOXP3(+). Lymphocyte populations were quantified with digital image analysis. Results were examined for their association with 5-year disease-free survival along with TNM stage and clinicopathologic variables. RESULTS: Longer disease-free survival was associated with higher CD3(+) counts at the invasive margin (IM) (p = 0.005), higher CD8(+) counts at the tumor center (TC) and IM (p = 0.002), a lower CD4(+)/CD8(+) ratio at the TC+IM (p = 0.027), and a higher CD8(+)/FOXP3(+) ratio at the TC+IM (p = 0.020). After multivariable analysis, CD8(+) at the TC+IM (p = 0.002), the CD8(+)/FOXP3(+) ratio at the TC+IM (p = 0.004), and the number of tumor-positive lymph nodes (p = 0.003) remained significant. CONCLUSIONS: This is the first prospective demonstration of the prognostic utility of immunoprofiling in colon cancer after nodal ultrastaging. Staging based on tumor immunoprofile can augment TNM staging and provide targets for specific immunotherapies.
Authors: Mary Garland-Kledzik; Abhineet Uppal; Yalda B Naeini; Stacey Stern; Richard Erali; Anthony J Scholer; Adam M Khader; Juan A Santamaria-Barria; Kathleen Cummins-Perry; Yi Zhou; Konstantinos I Votanopoulos; Perry Shen; Edward A Levine; Anton J Bilchik Journal: J Gastrointest Surg Date: 2020-12-02 Impact factor: 3.452
Authors: Juliana Noguti; Alfred A Chan; Bradley Bandera; Colin J Brislawn; Mladjan Protic; Myung S Sim; Janet K Jansson; Anton J Bilchik; Delphine J Lee Journal: Oncotarget Date: 2018-05-04
Authors: Faraz Bishehsari; Phillip A Engen; Robin M Voigt; Garth Swanson; Maliha Shaikh; Sherry Wilber; Ankur Naqib; Stefan J Green; Brandon Shetuni; Christopher B Forsyth; Abdulrahman Saadalla; Abu Osman; Bruce R Hamaker; Ali Keshavarzian; Khashayarsha Khazaie Journal: Cell Mol Gastroenterol Hepatol Date: 2019-11-02
Authors: Paulina Czajka-Francuz; Sylwia Cisoń-Jurek; Aleksander Czajka; Maciej Kozaczka; Jerzy Wojnar; Jerzy Chudek; Tomasz Francuz Journal: Int J Mol Sci Date: 2021-12-23 Impact factor: 5.923
Authors: Guilin Qiao; Lyonell B Kone; Evan H Phillips; Steve Seung-Young Lee; Grace E Brown; Salman R Khetani; Archana Thakur; Lawrence G Lum; Bellur S Prabhakar; Ajay V Maker Journal: Oncogene Date: 2022-02-17 Impact factor: 8.756
Authors: Douglas J Hartman; Madison Frank; Lindsey Seigh; Haroon Choudry; James Pingpank; Matthew Holtzman; David Bartlett; Nathan Bahary; Liron Pantanowitz; Reetesh K Pai Journal: Am J Surg Pathol Date: 2020-07 Impact factor: 6.298
Authors: Phillip M Kemp Bohan; Robert C Chick; Annelies T Hickerson; Lynn M Messersmith; Grant M Williams; Jessica L Cindass; Jamie Lombardo; Ryan Collins; Robert O Brady; Diane F Hale; George E Peoples; Timothy J Vreeland; Guy T Clifton Journal: Cancer Immunol Immunother Date: 2020-11-12 Impact factor: 6.630